percutaneous treatment of thoracic malignancy william moore, m.d. associate professor of radiology...
TRANSCRIPT
![Page 1: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/1.jpg)
Percutaneous Treatment of Thoracic Malignancy
William Moore, M.D.
Associate Professor of Radiology
Stony Brook University Medical Center
Union University10/19/2012
![Page 2: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/2.jpg)
Objectives:
Epidemiology of Lung Cancer. Technique of Percutaneous Ablation. Radiofrequency Biology of Cell Death. Cryobiology of Cell Death. Imaging Follow–up. Preliminary Data.
![Page 3: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/3.jpg)
Epidemiology of lung cancer.
Lung cancer is the leading cause of cancer related death for both men and women in the United States.
In 2009: estimated 219,440 cases of lung cancer
diagnosed in the US and 1.3 million cases worldwide.
159,000 deaths from lung cancer were estimated in the United States in 2009
![Page 4: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/4.jpg)
![Page 5: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/5.jpg)
![Page 6: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/6.jpg)
So how do we find a lung cancer?
![Page 7: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/7.jpg)
So how do we find a lung cancer?
Chest x-ray CT
![Page 8: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/8.jpg)
![Page 9: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/9.jpg)
![Page 10: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/10.jpg)
![Page 11: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/11.jpg)
![Page 12: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/12.jpg)
![Page 13: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/13.jpg)
![Page 14: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/14.jpg)
![Page 15: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/15.jpg)
So how do we find a lung cancer?
Chest x-ray CT Bronchoscopy Findings metastatic disease elsewhere
![Page 16: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/16.jpg)
Standard Therapy for Lung Cancer:
Lobectomy is the standard therapy for stage I non-small cell lung cancer (NSCLC).
5-year survivals as great as 80-90% and local recurrence rates of 5%.
Unfortunately, only 30% of cases are resectable at the time of diagnosis. Secondary other medical conditions (PFT)
![Page 17: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/17.jpg)
Limited Resection:
For the moderately compromised patient, sublobar resection is an option. The main concern with sublobar resection is
the increased local recurrence relative to lobectomy.
For patients who are unable to tolerate pulmonary resection, external beam radiation (XRT) has traditionally been used.
![Page 18: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/18.jpg)
Treatment results are inferior to those of resection. In a study of Stage 1 Lung cancers who
received XRT of at least 60 Gy. 3 year survival 19%.* 5-year survivals 12%.*
Median survival is estimated at 19.9 months.**
*Kupelian PA, Komaki R, Allen P. Int J Radiat Oncol Biol Phys. 1996;36:607-613.** Chest: 2002;121;1155-1158
External Beam Radiation:
![Page 19: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/19.jpg)
Chest: 2002;121;1155-1158Chest: 2007; 123; 193-200
XRT
No Rx
Surgical Resection
![Page 20: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/20.jpg)
So what else could we do?
![Page 21: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/21.jpg)
Local therapy has been tried
What is the goal? Cure
What could we use? Microwave Laser Radiofrequency Freezing Heating IRE
![Page 22: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/22.jpg)
General Ablation Technique:
CT guidance is used for ALL lung applications
We use general Anesthesia for all procedures. Total anesthesia time is about 1-1.5 hours.
![Page 23: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/23.jpg)
Start RFA
![Page 24: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/24.jpg)
RF Generator
Patient return/grounding pads
RFA Electrode
RFA technique:
![Page 25: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/25.jpg)
RFA technique:RITA/Angiodynamics
Starburst Probes We use the Starburst Talon 4 cm probe.
This has a flexible handle which is 20 cm long. Perfect for CT applications.
Sterile saline infusion pump system Saline goes into the patient and diffuses among
the lung propagating the RF signal (0.1cc/min)
![Page 26: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/26.jpg)
Cool-Tip Electrode
![Page 27: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/27.jpg)
RFA technique:Valley-labs
The single probe: This is for smaller lesions. There is a 3 cm exposed tip.
![Page 28: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/28.jpg)
Cluster tip probe.
Three separate tips are on this single shaft probe. This has a 3 cm tip exposure. With a 5-6 cm spherical kill zone
12-16 minute total burn
![Page 29: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/29.jpg)
RFA
Mechanisms of Cell Destruction
![Page 30: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/30.jpg)
Tumor Biology with RFA:
At 45 °C cellular swelling begins.The minimal acceptable tissue
temperature for cell death is 60 ° C. Cellular proteins are denatured
enzymes are deactivated and cellular death results.
![Page 31: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/31.jpg)
Tumor Biology with RFA:
At 105-115 °C charring of tissue can occur. Cavitation or gas formation also occur at
this temperature. The impedance (tissue resistance to
energy flow) increases dramatically. This is a problem in the lung because
of possible air emboli to the brain. Stroke is a known risk with RFA.
![Page 32: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/32.jpg)
Cryoablation This is a freezing procedure. Just like the RFA we place a needle into
the lesion and rather then heat it up we freeze it.
![Page 33: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/33.jpg)
Isotherm forms a 2.4 mm
Right AngleCryoProbe
DIAMETER(MM)
LENGTH(MM)
0oC 37 56
-20oC 24 44
-40oC 16 36
![Page 34: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/34.jpg)
PCT Technique:
Depends on the size of the lesion. Small lesions (1-2 cm)
Single Needle; place the needle in the center of the lesion.
![Page 35: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/35.jpg)
PCT Technique:
Larger Lesions (>2.0-3.5 cm)Cluster technique
Several needles clustered around the lesion.
![Page 36: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/36.jpg)
Ablation Protocol
We perform a freeze-thaw-freeze cycle on all tumors.
10 minute freeze (-140°C)
8 minute thaw (Never go above 0° C)
10 minute freeze 3 minute thaw to
remove the needle from the ice block.
Total Ablation time 28 minutes
![Page 37: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/37.jpg)
1996Argon Based
Joule-Thompson Cryoprobes
Principle of OperationPrinciple of Operation
25 °C (room temp.)
25 °C (room temp.)
-185 °C(liquid argon)
-185 °C(liquid argon)
Low Pressure Outlet
Argon Control
HoseHose ProbeProbe TipTip
Helium Control Orifice
Galil Medical Proprietary InformationGalil Medical Proprietary Information
Heat Exchanger
![Page 38: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/38.jpg)
Ice Ball Formation
Different gases have different Joule–Thomson (Kelvin) coefficientHelium is warmer at 1 atmosphere while most other gases aka Argon get colder.
![Page 39: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/39.jpg)
CryobiologyMechanisms of Cell Destruction
![Page 40: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/40.jpg)
Freezing tissue damages cells in two ways:
1. Direct damage (to the cells) at the time of cryoablation Slow cooling injury Fast cooling injury
2. Indirect damage (to the tissue) following cryoablation Ischemia Apoptosis
Freezing Damage Mechanisms
![Page 41: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/41.jpg)
When cells are frozen quickly: Water is trapped inside the cell because of
how fast the temperature decrease This results in Intracellular Ice Formation
(IIF) The cytoplasm becomes supercooled This damages the cell membrane. Holding the freeze causes recrystallization
increasing cell damage.
Direct Damage
![Page 42: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/42.jpg)
Direct Damage
When cells are frozen slowly: Ice forms in the extracellular matrix The cell dehydrate but now has more
concentrated cytoplasm Upon thawing cell rehydrates and expands
beyond the membrane resulting in lysis
![Page 43: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/43.jpg)
Indirect Damage
Two theories Blood vessel engorgement
Ice formation causes vessel wall engorgement and distention resulting in stasis.
Damage to the endothelial cells Much like direct causes but this results in
decreased blood flow to the tumor.
Final result necrosis
![Page 44: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/44.jpg)
Complications:for RFA and PCT
![Page 45: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/45.jpg)
Immediate complications:
Pneumothorax Small: 30% of our cases Up to 50% in
literature Large: 20%; all required chest tubes
Three required prolonged hospitalization.
Pulmonary Hemorrhage: Minor degrees in almost all cases.
Hemoptysis: Moderate (200 cc) in 1 of cases.
![Page 46: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/46.jpg)
Follow-up?
We follow patient with CT with contrast
And
Positron Emission Tomography (PET) imaging.
![Page 47: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/47.jpg)
Contrast CT
CT works by stopping the beam of radiation as it passes through a structure. The radiation is collected by the detector and
then depending on the density of the structure it will give a specific level of gray.
When we add contrast (aka Iodine) structures that are vascular have more iodine in them More iodine means more attenuation of x-ray
beams.
![Page 48: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/48.jpg)
![Page 49: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/49.jpg)
PET
Works by given a high energy particle; 1.22 MeV particle to the patient which is
coupled to FDG-a glucose analog. This particle is radioactive and breaks down
with time. T1/2 3 hours. We inject a standard amount 10-13 mCu and
image 1 hour later.
![Page 50: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/50.jpg)
PET
The particle decays by annihilation. This means that the particle breaks in half and
goes in opposite directions. 511 keV at 180 degrees to each other.
![Page 51: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/51.jpg)
PET
The detector will only image the particles that hit the detectors at the same time at 180 degrees.
The glucose is held in the metabolically active cells because of the fluoride which is added to the glucose.
![Page 52: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/52.jpg)
6 monthSUV 1
12 monthSUV 3.8
![Page 53: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/53.jpg)
1 month postPre-treatment
3 month post 6 month post
![Page 54: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/54.jpg)
Aorta
![Page 55: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/55.jpg)
Pre-treatment 1 year post-treatment
![Page 56: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/56.jpg)
![Page 57: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/57.jpg)
Conclusions:
RFA and Cryoablation are safe alternatives to standard non-surgical therapy for lung cancer and pulmonary metastatic disease.
Long term data in the lung is starting to surface for RFA but not PCT.
Carefully, performed clinical trials are necessary to determine the exact role of these interventions in patients with lung cancer.
![Page 58: Percutaneous Treatment of Thoracic Malignancy William Moore, M.D. Associate Professor of Radiology Stony Brook University Medical Center Union University](https://reader035.vdocuments.net/reader035/viewer/2022070306/5517e3af550346c6568b4618/html5/thumbnails/58.jpg)
References: Wang H, Littrup P, Duan Y, et al. Thoracic Masses Treated with
Percutaneous Cryotherapy: Initial Experience with More than 200 Procedures. Radiology 2005; 235:289–298
Swensen SJ, Viggiano RW, Midthun DE, et al Lung nodule enhancement at CT: multicenter study. Radiology 2000; 214:73–80
Shankar LK, Hoffman JM, Bacharach S, etal. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-66
Hoffman NE, Bischof JC. The Cryobiology of Cryosurgical Injury. Urology 2002 (Suppl 2A): 40-49.
de Baere T, Palussiere J, Auperin A, et al Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006 Aug;240(2):587-96.
Zemlyak A, Moore WH, and Bilfinger TV. Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer. Journal of the American College of Surgeons 211(1):68-72, 2010